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Background
Cardiac hypertrophy is an adaptive response of the heart
to many cardio-vascular disorders including hypertension,
infarction and defects of the valves. Elevated levels of car-
diac cyclic guanosine-3',5'-monophosphate (cGMP) acti-
vate cGMP-dependent protein kinase I (cGKI), which
reportedly exhibited either anti-fibrotic and anti-hyper-
trophic effects or did not change the cardiac remodeling
response. Based on these conflicting results, we and others
suggested that the ability of natriuretic peptides (NP) to
oppose detrimental changes via cGMP/cGKI might be
strongly influenced by the stress stimuli that actually trig-
ger the harmful events i.e. Angiotensin II (Ang II) modu-
lating multiple reno-vascular and cardiac functions via G
q-coupled Ang II type 1 receptors (AT1Rs). It is the over-
all aim of this study to dissect the molecular details under-
lying the cross-talk between the NP/cGMP/cGKI pathway
and AngII/AT1R signaling in the heart.
Methods
We investigated the role of cGKI and its substrate
cysteine-rich LIM-only protein 4 (CRP4) in neuro-hor-
monal induced heart hypertrophy upon Angiotensin II
(Ang II) infusions (2 mg/kg/d) and in transgenic mice
overexpressing the human AT1R specifically in cardio-
myocytes (MHC-AT1Rtg/+). Physiological growth adap-
tion of the heart muscle was studied by healthy exercise
training using a duration-controlled swimming protocol
in CRP4 wild type (CRP4-WT) and CRP4 knockout
(CRP4-KO) animals. The extent of the cardiac growth
response was defined by referring changes in heart-weight
to body-weight (HW/BW) or tibia length (HW/TL), Sirius
Red staining as a quantitative measure of fibrosis and by
echocardiographic parameters in CRP4-KO and double-
mutant MHC-AT1Rtg/+ x CRP4-KO mice in comparison
to age- and littermate CRP4-WT and MHC-AT1Rtg/+ x
CRP4-WT mice, respectively. Hypertrophic and fibrotic
marker genes, putative effects of Ang II and AT1R overex-
pression on components of the NP/cGMP/cGKI pathway
and the levels of other members of the CRP protein family
i.e. CRP1 and the muscle LIM protein CRP3/MLP were
analyzed in total mRNA and protein preparations isolated
from healthy and hypertrophic ventricles. These experi-
ments were corroborated by investigating the myocardial
dynamics of the CRP4 interactome ±Ang II.
Results
HW/BW and HW/TL ratios between CRP4-KO and
CRP4-WT mice did not differ at baseline or upon
healthy exercise; however, in response to the Ang II
infusions cardiomyocyte size, normalized heart ratios
and total cardiac mass as well as the amount of intersti-
tial fibrosis were elevated in CRP4-negative hearts,
whereas anti-fibrotic factors such as BNP were lower in
the absence of CRP4. Evidence for a protein complex
containing cGKI and CRP4 in lysates obtained from
hypertrophic CRP4-WT hearts provides a link between
cGMP/cGKI and CRP4 in a setting of amplified Ang II
signaling. Our ongoing analyses of the MHC-AT1Rtg/+
mouse model, which develops a progressive cardiac
remodeling phenotype in the absence of hypertension,
identified an increase in basal cGMP levels and high
abundance of cardiac cGKI protein confirming activa-
tion of the cGMP/cGKI pathway under these conditions.
Finally, amplified AT1R signaling in the CM caused a
gradual decline in multiple parameters of cardiac function
(percent fractional shortening (%FS), ejection fraction (EF)
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etc.), which were all significantly more distorted in double-
mutant MHC-AT1Rtg/+ x CRP4-KOs than in MHC-
AT1Rtg/+ x CRP4-WT mice.
Conclusion
Increased susceptibility of CRP4-deficient hearts to both
chronic Ang II exposure and AT1R overexpression in the
cardiomyocyte identifies CM CRP4 as novel anti-hyper-
trophic and anti-fibrotic factor acting downstream of
cGMP/cGKI.
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